BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Benitec, Inc. (BLT.AX) Release: Hepatitis C Trial To Proceed


1/14/2014 9:04:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Sydney Australia, 14th January 2014: RNAi - based therapeutics company Benitec Biopharma Limited (ASX: BLT) today announced that the US Food and Drug Administration (FDA) has advised the Company that it may proceed with it s ‘f irst in man’ clinical trial for TT - 034, a ddRNAi - based therapeutic, designed to treat Hepatitis C with a single injection .

This follows the FDA’s review of Benitec’s Investigational New Drug (IND) application, which was filed on 6 December 2013.

Benitec Biopharma’s CEO and Managing Director, Peter French said, “We are very pleased with this outcome which establishes Benitec as a clinical stage company .”

For further information, please contact the persons outlined below, or visit the Benitec website at www.benitec.com .

Company
Carl Stubbings
Chief Business Officer
Tel: +61 (2) 9555 6986
Email:
cstubbings@benitec.com

Investor relations
Jane Lowe
Buchan Consulting
Te
l: +61 (2) 9237 2807
Email:
jlowe@buchanwe.com.au

About Benitec Biopharma Limited:
Benitec Biopharma Limited is an ASX - listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in - house and partnered therapeutic programs based on its patented ge ne - silencing technology, ddRNAi . Benitec is developing treatments for chronic and life - threatening human conditions such as Hepatitis C , Hepatitis B, wet age - related macular degeneration, cancer - associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs t owards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington’s disease. For more information on Benitec refer to the Company’s website at www.benitec.com .

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES